RTW forms Prolium to develop Keymed Biosciences' CD20×CD3 bispecific CM355 outside Asia for $17.5M upfront, part of growing ...

Welcome back to the new and improved Endpoints Weekly! This week we’ll be recapping the JP Morgan Healthcare Conference, IRA ...

Novo Nordisk's high-dose Wegovy shows 20.7% weight loss in Phase 3 but falls short of Eli Lilly's Zepbound, raising questions ...

The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...

CMS didn't wait for President-elect Donald Trump to take office before issuing its second list of drugs to be negotiated ...

Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze ...

NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent.

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...

The FDA approved Eli Lilly’s Omvoh in Crohn’s disease, the company announced Wednesday, handing the drug its second ...

The Department of Health and Human Services says Vertex is 'grasping at straws' in a lawsuit challenging the agency’s ...

FDA approves AstraZeneca's Calquence as first BTK inhibitor for first-line mantle cell lymphoma, leading BeiGene's Brukinsa ...

It’s time for one last look at the biotech numbers for 2024. And you might be surprised by some bullish charts below — ...